Theravance Biopharma, Inc. (TBPH) Stock
Theravance Biopharma, Inc.

Company profile
Theravance Biopharma reported revenue of $107.46 million for fiscal year 2025. In Q2 2026 (the quarter ended June 30, 2026) revenue was $20.73 million. United States was its largest region in fiscal year 2025, with 70% of revenue. In Q2 2026 it reported a net loss of $5.90 million, against net income of $54.84 million a year earlier. Our analysis of its filings shows revenue growing from $57.42 million in fiscal year 2023 to $107.46 million in fiscal year 2025, 36.8% a year on average. Theravance Biopharma reports about 90 full-time employees.
What stands out
- Revenue rose 66.9% in fiscal year 2025, from $64.38 million in fiscal year 2024, after a rise of 12.1% the year before.
- It returned to a profit in fiscal year 2025, $105.90 million, after 2 years of net losses ($56.42 million in fiscal year 2024).
- Revenue turned down in Q2 2026: down 20.9% from a year before.
- It spent $37.41 million on research and development in fiscal year 2025, 34.8% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.
Largest shareholders
- Madison Avenue Partners LP18.47%
- Weiss Asset Management LP14.48%
- Weiss Asset Management LP14.48%
- Newtyn Management LLC9.40%
- BlackRock Advisors LLC7.82%
Share of the company, as of May 19, 2026
Leadership
- Rick E. Winningham M.B.A. — CEO & Director, 65
- Aziz Sawaf C.F.A. — Senior VP of Operations Strategy & CFO, 43
- Rhonda F. Farnum — Chief Business Officer and Senior VP of Commercial & Medical Affairs, 60
- Stuart Knight — Senior VP of IT&I and Chief Information Officer
- Stacy L. Pryce — Senior VP & Chief Strategy Officer
In the news
- Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)Defense World ·
- CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial AnalysisDefense World ·
- Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 OutlookMarketBeat ·
- Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head ContrastDefense World ·
How much revenue does Theravance Biopharma make?
Theravance Biopharma reported $107.46 million in revenue for fiscal year 2025, up 66.9% from $64.38 million in fiscal year 2024. In Q2 2026 revenue was $20.73 million.
Where does Theravance Biopharma make most of its revenue?
United States: 70% of revenue by region in fiscal year 2025, followed by Europe (30%).
What companies are similar to Theravance Biopharma?
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Upstream Bio, Inc. (UPB), Innoviva, Inc. (INVA), Savara Inc. (SVRA), 4D Molecular Therapeutics, Inc. (FDMT).
How has Theravance Biopharma's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $55.31 million; FY2022, $51.35 million; FY2023, $57.42 million; FY2024, $64.38 million; FY2025, $107.46 million.
Has Theravance Biopharma made a profit in recent years?
Net income by fiscal year: FY2021, a loss of $199.43 million; FY2022, $872.13 million; FY2023, a loss of $55.19 million; FY2024, a loss of $56.42 million; FY2025, $105.90 million. It reported a net loss in 3 of these 5 years.
Data as of .
How to cite: DataPorium, “Theravance Biopharma, Inc. (TBPH)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/TBPH